Effect of Fedratinib Versus Best Available Therapy on Patient-Reported Outcomes in Patients with Myelofibrosis Who Were Previously Treated with Ruxolitinib: Results from the Phase 3 FREEDOM2 Trial

被引：0
|
作者：
Harrison, Claire [1 ]
Lord-Bessen, Jennifer [2 ]
Shi, Ling [3 ]
Guo, Shien [3 ]
Yucel, Aylin [2 ]
Zissler, Dorothy [2 ]
Jones, Shalon [2 ]
Slaff, Samantha [2 ]
机构：
[1] Guys & St Thomas NHS Fdn Trust, London, England
[2] Bristol Myers Squibb, Princeton, NJ USA
[3] Evidera, Bethesda, MD USA
来源：
BLOOD | 2024年 / 144卷
关键词：
D O I：
10.1182/blood-2024-198368
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：6624 / 6625
页数：2
相关论文
共 50 条
  • [31] Patient-reported outcomes with abrocitinib treatment in patients with moderate to severe atopic dermatitis: Results from a randomized, phase 3 clinical trial
    Silverberg, Jonathan I.
    Cohen, Arnon D.
    Stander, Sonja
    Feeney, Claire
    Valdez, Hernan
    Biswas, Pinaki
    Cameron, Michael C.
    DiBonaventura, Marco
    Gerber, Robert A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2020, 83 (06) : AB35 - AB35
  • [32] Relationship Between Patient-Reported Outcomes (PROs) and Health-Related Quality of Life (HRQoL) and Efficacy in Patients with Myelofibrosis in the Phase III Persist-1 Trial of Pacritinib Vs. Best Available Therapy (BAT)
    Mesa, Ruben A.
    Harrison, Claire N.
    Cervantes, Francisco
    Dean, James P.
    Wang, Lixia
    Granston, Tanya
    Yang, Yoojung
    Vannucchi, Alessandro M.
    Mead, Adam
    BLOOD, 2015, 126 (23)
  • [33] Patient-reported outcomes in patients with relapsed or refractory follicular lymphoma treated with zanubrutinib plus obinutuzumab versus obinutuzumab monotherapy: results from the ROSEWOOD trial
    Trotman, Judith
    Zinzani, Pier Luigi
    Song, Yuqin
    Delarue, Richard
    Kim, Pil
    Ivanova, Elena
    Korde, Rasika
    Mayer, Jiri
    De Oliveira, Ana C.
    Assouline, Sarit E.
    Flowers, Christopher R.
    Barnes, Gisoo
    CURRENT MEDICAL RESEARCH AND OPINION, 2024, 40 (11) : 1863 - 1871
  • [34] Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
    Steffen Koschmieder
    Susanne Isfort
    Clemens Schulte
    Lutz Jacobasch
    Thomas Geer
    Marcel Reiser
    Michael Koenigsmann
    Bernhard Heinrich
    Jürgen Wehmeyer
    Eyck von der Heyde
    Hans Tesch
    Benedikt Gröschl
    Petra Bachhuber
    Susanne Großer
    Heike L. Pahl
    Annals of Hematology, 2023, 102 : 3383 - 3399
  • [35] Clinical Effectiveness and Safety of Momelotinib Compared with Continued Ruxolitinib or Best Available Therapy in Patients with Myelofibrosis Who Required RBC Transfusions: Subgroup Analysis of the Phase 3 Simplify-2 Study
    Harrison, Claire N.
    Vannucchi, Alessandro Maria
    Recher, Christian
    Passamonti, Francesco
    Gerds, Aaron T.
    Hernandez Boluda, Juan Carlos
    Yacoub, Abdulraheem
    Sirhan, Shireen
    Kawashima, Jun
    Patel, Bharat
    Strouse, Bryan
    Platzbecker, Uwe
    BLOOD, 2023, 142
  • [36] PATIENT-REPORTED OUTCOMES (PROS) IN PERSIST-1: A RANDOMIZED, MULTI-COUNTRY PHASE III TRIAL OF THE JAK2 INHIBITOR PACRITINIB (PAC) VS. BEST AVAILABLE THERAPY (BAT) IN MYELOFIBROSIS (MF)
    Mesa, R.
    Vannucchi, A.
    Mead, A.
    Wang, L.
    Yang, Y.
    Harrison, C.
    HAEMATOLOGICA, 2015, 100 : 336 - 337
  • [37] Association Between Clinically Meaningful Improvements in Patient-Reported Outcomes and Stringent Measures of Disease Activity in Patients with Psoriatic Arthritis Treated with Upadacitinib versus Placebo or Adalimumab: Results from a Phase 3 Trial
    Gossec, Laure
    Damjanov, Nemanja
    Tsuji, Shigeyoshi
    Lertratanakul, Apinya
    Lippe, Ralph
    Patel, Jayeshkumar
    Zueger, Patrick
    de Vlam, Kurt
    ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3986 - 3989
  • [38] ASSOCIATION BETWEEN CLINICALLY MEANINGFUL IMPROVEMENTS IN PATIENT-REPORTED OUTCOMES AND STRINGENT MEASURES OF DISEASE ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS TREATED WITH UPADACITINIB VERSUS PLACEBO OR ADALIMUMAB: RESULTS FROM A PHASE 3 TRIAL
    Gossec, L.
    Damjanov, N.
    Tsuji, S.
    Lertratanakul, A.
    Lippe, R.
    Patel, J.
    Zueger, P.
    De Vlam, K.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1569 - 1570
  • [39] A Phase 3, Open-Label, Randomized Study Evaluating the Efficacy and Safety of Navitoclax Plus Ruxolitinib Versus Best Available Therapy in Patients with Relapsed/Refractory Myelofibrosis (TRANSFORM-2)
    Dilley, Kimberley
    Harb, Jason
    Jalaluddin, Muhammad
    Hutti, Jessica E.
    Potluri, Jalaja
    BLOOD, 2020, 136
  • [40] NETAKIMAB IMPROVES PATIENT-REPORTED OUTCOMES IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A RANDOMIZED DOUBLE-BLIND PHASE 3 TRIAL (PATERA)
    Korotaeva, T.
    Gaydukova, I.
    Mazurov, V.
    Samtsov, A.
    Khayrutdinov, V.
    Bakulev, A.
    Kokhan, M.
    Kundzer, A.
    Soroka, N.
    Dokukina, E.
    Eremeeva, A.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1691 - 1692
12345